Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 6, 2014, Pages 3177-3181

  Werth, Brian J ^a   Barber, Katie E ^a   Ireland, Cortney E ^a   Rybak, Michael J ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE; CEFTAROLINE FOSAMIL; DAPTOMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; DRUG COMBINATION;

ARTICLE; BACTERIAL ENDOCARDITIS; BACTERICIDAL ACTIVITY; DAPTOMYCIN NONSUSCEPTIBLE METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; DISEASE SIMULATION; DRUG HALF LIFE; ENDOCARDIUM; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; PRIORITY JOURNAL; SIMULATED ENDOCARDIAL VEGETATION; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; BACTERIAL COUNT; COMPUTER SIMULATION; DRUG COMBINATION; DRUG EFFECTS; ENDOCARDITIS, BACTERIAL; HALF LIFE TIME; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; STAPHYLOCOCCAL INFECTIONS;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; COLONY COUNT, MICROBIAL; COMPUTER SIMULATION; DAPTOMYCIN; DRUG COMBINATIONS; ENDOCARDITIS, BACTERIAL; HALF-LIFE; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 84901251282     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00088-14     Document Type: Article

References (30)

1. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak MJ, Talan DA, Chambers HF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin. Infect. Dis. 52:285-292. http://dx.doi.org/10.1093/cid/cir034.
2. Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC, Jr., Eliopoulos GM. 2006. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob. Agents Chemother. 50:1581-1585. http://dx.doi.org/10.1128/AAC.50.4.1581-1585.2006.
3. Werth BJ, Vidaillac C, Murray KP, Newton KL, Sakoulas G, Nonejuie P, Pogliano J, Rybak MJ. 2013. Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycinintermediate Staphylococcus aureus (VISA) and heterogeneous VISA. Antimicrob. Agents Chemother. 57:2376-2379. http://dx.doi.org/10.1128/AAC.02354-12.
4. Cui L, Tominaga E, Neoh HM, Hiramatsu K. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:1079-1082. http://dx.doi.org/10.1128/AAC.50.3.1079-1082.2006.
5. Kelley PG, Gao W, Ward PB, Howden BP. 2011. Daptomycin nonsusceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J. Antimicrob. Chemother. 66:1057-1060. http://dx.doi.org/10.1093/jac/dkr066.
6. Tenover FC, Sinner SW, Segal RE, Huang V, Alexandre SS, McGowan JE, Jr., Weinstein MP. 2009. Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy. Int. J. Antimicrob. Agents 33:564-568. http://dx.doi.org/10.1016/j.ijantimicag. 2008.12.010.
7. Avery LM, Steed ME, Woodruff AE, Hasan M, Rybak MJ. 2012. Daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole. Antimicrob. Agents Chemother. 56:5990-5993. http://dx.doi.org/10.1128/AAC.01046-12.
8. Mariani PG, Sader HS, Jones RN. 2006. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy. J. Antimicrob. Chemother. 58:481-483. http://dx.doi.org/10.1093/jac/dkl256.
9. Fowler VG, Jr., Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fatkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE, S. aureus Endocarditis and Bacteremia Study Group. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355: 653-665. http://dx.doi.org/10.1056/NEJMoa053783.
10. Boucher HW, Sakoulas G. 2007. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin. Infect. Dis. 45:601-608. http://dx.doi.org/10.1086/520655.
11. Villegas-Estrada A, Lee M, Hesek D, Vakulenko SB, Mobashery S. 2008. Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition ofPBP2a by two anti-MRSA beta-lactam antibiotics. J. Am. Chem. Soc. 130:9212-9213. http://dx.doi.org/10.1021/ja8029448.
12. Steed ME, Rybak MJ. 2010. Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens. Pharmacotherapy 30:375-389. http://dx.doi.org/10.1592/phco.30.4.375.
13. Werth BJ, Sakoulas G, Rose WE, Pogliano J, Tewhey R, Rybak MJ. 2013. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycinintermediate Staphylococcus aureus in a pharmacokinetic/ pharmacodynamic model. Antimicrob. Agents Chemother. 57:66-73. http://dx.doi.org/10.1128/AAC.01586-12.
14. Werth BJ, Steed ME, Kaatz GW, Rybak MJ. 2013. Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the "seesaw effect". Antimicrob. Agents Chemother. 57:2664-2668. http://dx.doi.org/10. 1128/AAC.02308-12.
15. Steed M, Vidaillac C, Rybak MJ. 2011. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillinresistant Staphylococcus aureus strains in an in vitro pharmacokinetic/ pharmacodynamic model. Antimicrob. Agents Chemother. 55:3522-3526.
16. Vidaillac C, Leonard SN, Rybak MJ. 2009. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycinintermediate S. aureus in a hollow fiber model. Antimicrob. Agents Chemother. 53:4712-4717. http://dx.doi.org/10.1128/AAC.00636-09.
17. File TM, Jr., Wilcox MH, Stein GE. 2012. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin. Infect. Dis. 55(Suppl 3):S173-S180. http://dx.doi.org/10.1093/cid/cis559.
18. Lin JC, Aung G, Thomas A, Jahng M, Johns S, Fierer J. 2013. The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J. Infect. Chemother. 19:42-49. http://dx.doi.org/10.1007/s10156-012-0449-9.
19. Ho TT, Cadena J, Childs LM, Gonzalez-Velez M, Lewis JS, Jr. 2012. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J. Antimicrob. Chemother. 67: 1267-1270. http://dx.doi.org/10.1093/jac/dks006.
20. Jacqueline C, Amador G, Batard E, Le Mabecque V, Miegeville AF, Biek D, Caillon J, Potel G. 2011. Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptideintermediate Staphylococcus aureus. J. Antimicrob. Chemother. 66:863-866. http://dx.doi.org/10.1093/jac/dkr019.
21. Jacqueline C, Caillon J, Le Mabecque V, Miegeville AF, Hamel A, Bugnon D, Ge JY, Potel G. 2007. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob. Agents Chemother. 51:3397-3400. http://dx.doi.org/10.1128/AAC.01242-06.
22. Rose WE, Schulz LT, Andes D, Striker R, Berti AD, Hutson PR, Shukla SK. 2012. Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrob. Agents Chemother. 56:5296-5302. http://dx.doi.org/10.1128/AAC.00797-12.
23. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. CLSI document M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.
24. Blaser J. 1985. In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J. Antimicrob. Chemother. 15(Suppl A):125-130. http://dx.doi.org/10.1093/jac/15.suppl-A.125.
25. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. 2006. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob. Agents Chemother. 50:3245-3249. http://dx.doi.org/10.1128/AAC.00247-06.
26. Jongsma K, Joson J, Heidari A. 2013. Ceftaroline in the treatment of concomitant methicillin-resistant and daptomycin-non-susceptible Staphylococcus aureus infective endocarditis and osteomyelitis: case report. J. Antimicrob. Chemother. 68:1444-1445. http://dx.doi.org/10.1093/jac/dkt009.
27. Bayer AS, Schneider T, Sahl HG. 2013. Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann. N. Y. Acad. Sci. 1277:139-158. http://dx.doi.org/10.1111/j.1749-6632.2012.06819.x.
28. Mehta S, Singh C, Plata KB, Chanda PK, Paul A, Riosa S, Rosato RR, Rosato AE. 2012. Beta-lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob. Agents Chemother. 56:6192-6200. http://dx.doi.org/10.1128/AAC.01525-12.
29. Sakoulas G, Bayer AS, Pogliano J, Tsuji BT, Yang SJ, Mishra NN, Nizet V, Yeaman MR, Moise PA. 2012. Ampicillin enhances daptomycin-And cationic host defense peptide-mediated killing of ampicillin-And vancomycin-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 56: 838-844. http://dx.doi.org/10.1128/AAC.05551-11.
30. Barber KE, Werth BJ, Rybak MJ. 2013. Evaluation of therapeutic deescalation of the novel combination of ceftaroline (CPT) plus daptomycin (DAP) against DAP non-susceptible (DNS) methicillin-resistant Staphylococcus aureus (MRSA) in an in vitrohollow-fiber pharmacokinetic/ pharmacodynamic model, abstr A-467. Abstr. 53rd Intersci. Conf. Antimicrob. Agents Chemother., Denver, CO.